Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,018.40
(
-2.10%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
101.44
(
2.70%
)
Bitcoin
69,108.95
(
-3.08%
)
News Focus
News Focus
Post# of 257294
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122814
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 177040

Monday, 04/21/2014 1:47:14 PM

Monday, April 21, 2014 1:47:14 PM

Post# of 257294
Actually, Idit, I don’t recall MNTA’s having cited any external “experts” to support its contention that generic Copaxone is approvable under the 505(j) pathway.

The press release Teva issued on Saturday (#msg-100823586) suggests to me that Teva’s corporate culture still needs a lot of work.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today